Published in J Am Soc Nephrol on December 01, 2004
Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci U S A (2008) 2.06
Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care (2009) 1.33
Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. Am J Physiol Renal Physiol (2009) 1.13
Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats. Am J Pathol (2010) 1.09
Comparative effects of different modes of renin angiotensin system inhibition on hypercholesterolaemia-induced atherosclerosis. Br J Pharmacol (2012) 1.03
The effect of direct renin inhibition alone and in combination with ACE inhibition on endothelial function, arterial stiffness, and renal function in type 1 diabetes. Diabetes Care (2012) 0.92
Therapeutic modalities in diabetic nephropathy: standard and emerging approaches. J Gen Intern Med (2011) 0.92
The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. Vasc Health Risk Manag (2008) 0.90
Clinical relevance of local Renin Angiotensin systems. Front Endocrinol (Lausanne) (2014) 0.89
Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination. Vasc Health Risk Manag (2010) 0.87
Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension. Hypertension (2012) 0.86
Reversibility of the effects of aliskiren in the renal versus systemic circulation. Clin J Am Soc Nephrol (2011) 0.84
Direct renin inhibition--a promising strategy for renal protection? Med Sci Monit (2013) 0.84
Application of direct renin inhibition to chronic kidney disease. Cardiovasc Drugs Ther (2010) 0.84
Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials. PLoS One (2013) 0.82
Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. Br J Clin Pharmacol (2006) 0.82
Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy. Vasc Health Risk Manag (2008) 0.82
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors. Vasc Health Risk Manag (2009) 0.81
Add-on aliskiren elicits stronger renoprotection than high-dose valsartan in type 2 diabetic KKAy mice that do not respond to low-dose valsartan. J Pharmacol Sci (2012) 0.81
Molecular mechanism of vitamin D in the cardiovascular system. J Investig Med (2011) 0.81
Aliskiren--an orally active renin inhibitor. Review of pharmacology, pharmacodynamics, kinetics, and clinical potential in the treatment of hypertension. Vasc Health Risk Manag (2007) 0.80
Additive effects of cilnidipine, an L-/N-type calcium channel blocker, and an angiotensin II receptor blocker on reducing cardiorenal damage in Otsuka Long-Evans Tokushima Fatty rats with type 2 diabetes mellitus. Drug Des Devel Ther (2014) 0.78
Central Pressure and Biomarker Responses to Renin Inhibition with Hydrochlorothiazide and Ramipril in Obese Hypertensives: The ATTAIN Study. Cardiorenal Med (2011) 0.78
First-line treatment of hypertension: critical appraisal of potential role of aliskiren and hydrochlorothiazide in a fixed combination. Integr Blood Press Control (2010) 0.78
Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug. Am J Med (2008) 0.78
Aliskiren - an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertension. Arch Med Sci (2013) 0.78
Plasma renin activity and risk of cardiovascular and mortality outcomes among individuals with elevated and nonelevated blood pressure. Kidney Res Clin Pract (2016) 0.77
Role of aliskiren in blood pressure control and renoprotection. Int J Nephrol Renovasc Dis (2011) 0.77
Renoprotection, renin inhibition, and blood pressure control: the impact of aliskiren on integrated blood pressure control. Integr Blood Press Control (2010) 0.77
Renin and cardiovascular disease: Worn-out path, or new direction. World J Cardiol (2011) 0.76
Aliskiren in hypertension: evidence for its potential therapeutic value. Core Evid (2005) 0.75
The critical role of the central nervous system (pro)renin receptor in regulating systemic blood pressure. Pharmacol Ther (2016) 0.75
Aliskiren and valsartan combination therapy for the management of hypertension. Vasc Health Risk Manag (2010) 0.75
Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension. Expert Rev Cardiovasc Ther (2012) 0.75
Management of Diabetic Nephropathy in the Elderly: Special Considerations. J Nephrol Ther (2012) 0.75
Aliskiren: An orally active renin inhibitor. J Pharm Bioallied Sci (2011) 0.75
Renin Angiotensin Aldosterone Inhibition in the Treatment of Cardiovascular Disease. Pharmacol Res (2017) 0.75
Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation (2011) 2.71
[Critical appraisal of medical literature: an essential tool to practice medicine]. Presse Med (2008) 2.53
Transplantation of cardiac-committed mouse embryonic stem cells to infarcted sheep myocardium: a preclinical study. Lancet (2005) 2.36
Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. J Am Coll Cardiol (2011) 2.29
Masked hypertension: a systematic review. J Hypertens (2008) 2.10
Comparison of human skeletal myoblasts and bone marrow-derived CD133+ progenitors for the repair of infarcted myocardium. J Am Coll Cardiol (2004) 1.79
Are two-dimensional CT measurements of small noncalcified pulmonary nodules reliable? Radiology (2004) 1.78
Pulmonary nodules: preliminary experience with three-dimensional evaluation. Radiology (2004) 1.62
Alcohol-attributable injuries in admissions to a swiss emergency room--an analysis of the link between volume of drinking, drinking patterns, and preattendance drinking. Alcohol Clin Exp Res (2006) 1.45
Prorenin contributes to angiotensin peptide formation in transgenic rats with rat prorenin expression targeted to the liver. Hypertension (2009) 1.44
N-terminal pro-brain natriuretic peptide--a promising biomarker for the diagnosis of left ventricular hypertrophy in hypertensive women. Arch Cardiovasc Dis (2008) 1.43
Health insurance coverage is the single most prominent socioeconomic factor associated with cardiovascular drug delivery in the French population. J Hypertens (2012) 1.40
Elevated growth-arrest-specific protein 6 plasma levels in patients with severe sepsis. Crit Care Med (2006) 1.37
Dual renin-angiotensin system blockade restores blood pressure-renin dependency in individuals with low renin concentrations. J Hypertens (2003) 1.37
Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable? Eur Radiol (2006) 1.23
Haemodynamic effects of dual blockade of the renin-angiotensin system in spontaneously hypertensive rats: influence of salt. J Hypertens (2004) 1.13
Activity assays and immunoassays for plasma Renin and prorenin: information provided and precautions necessary for accurate measurement. Clin Chem (2009) 1.12
Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation (2004) 1.09
Enhancement of the functional benefits of skeletal myoblast transplantation by means of coadministration of hypoxia-inducible factor 1alpha. J Thorac Cardiovasc Surg (2005) 0.98
Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy. Eur Radiol (2008) 0.96
Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos (2007) 0.95
Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Clin Cancer Res (2005) 0.93
Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans. J Clin Invest (2005) 0.92
Can cold or heat shock improve skeletal myoblast engraftment in infarcted myocardium? Transplantation (2005) 0.92
Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. Clin J Am Soc Nephrol (2007) 0.90
Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet (2006) 0.89
Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans. Hypertension (2004) 0.87
20-Year prevalence projections for dementia and impact of preventive policy about risk factors. Eur J Epidemiol (2013) 0.87
Mice chronically fed a westernized experimental diet as a model of obesity, metabolic syndrome and osteoporosis. Eur J Nutr (2006) 0.87
Compliance of abdominal aortic aneurysms: evaluation of tissue Doppler imaging. Ultrasound Med Biol (2004) 0.86
Renin inhibitors and cardiovascular and renal protection: an endless quest? Cardiovasc Drugs Ther (2013) 0.86
Does the functional efficacy of skeletal myoblast transplantation extend to nonischemic cardiomyopathy? Circulation (2004) 0.85
A computer decision aid for medical prevention: a pilot qualitative study of the Personalized Estimate of Risks (EsPeR) system. BMC Med Inform Decis Mak (2003) 0.84
How to calculate left ventricular mass in routine practice? An echocardiographic versus cardiac magnetic resonance study. Arch Cardiovasc Dis (2011) 0.83
Personalized versus non-personalized computerized decision support system to increase therapeutic quality control of oral anticoagulant therapy: an alternating time series analysis. BMC Health Serv Res (2004) 0.83
Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk. J Hypertens (2002) 0.83
Very low oral doses of vitamin B-12 increase serum concentrations in elderly subjects with food-bound vitamin B-12 malabsorption. J Nutr (2007) 0.83
Skeletal myoblast transplantation through a catheter-based coronary sinus approach: an effective means of improving function of infarcted myocardium. Eur Heart J (2005) 0.82
Multiple ascending dose study with the new renin inhibitor VTP-27999: nephrocentric consequences of too much renin inhibition. Hypertension (2014) 0.82
Investigation of aldosterone-synthase inhibition in rats. J Hypertens (2006) 0.82
Influence of blood sampling procedure on plasma concentrations of matrix metalloproteinases and their tissue inhibitors. Clin Exp Pharmacol Physiol (2008) 0.81
Effect of contrasted sodium diets on the pharmacokinetics and pharmacodynamic effects of renin-angiotensin system blockers. Hypertension (2013) 0.81
Clearance systems in the brain-implications for Alzheimer diseaser. Nat Rev Neurol (2016) 0.80
Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy. Am J Physiol Endocrinol Metab (2005) 0.80
Physiologic consequences of vasopeptidase inhibition in humans: effect of sodium intake. J Am Soc Nephrol (2002) 0.80
Thromboangiitis obliterans and endothelial function. Eur J Clin Invest (2010) 0.79
Novel risk factors for premature peripheral arterial occlusive disease in non-diabetic patients: a case-control study. PLoS One (2013) 0.79
Relevance of the evaluation criteria used in clinical trials for Alzheimer's disease. Therapie (2009) 0.79
Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans. Clin Pharmacol Ther (2006) 0.79
The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren. J Hypertens (2007) 0.79
Altered renin synthesis and secretion in the kidneys of heterozygous mice with a null mutation in the TGF-beta(2) gene. Exp Nephrol (2002) 0.79
Anemia normalization in patients with type 2 diabetes and chronic kidney disease: results of the NEPHRODIAB2 randomized trial. J Diabetes Complications (2011) 0.78
Effects of aliskiren, a direct Renin inhibitor, on cardiac repolarization and conduction in healthy subjects. J Clin Pharmacol (2008) 0.78
A vaccine for hypertension. J Hypertens (2007) 0.78
Compliance of abdominal aortic aneurysms evaluated by tissue Doppler imaging: correlation with aneurysm size. J Vasc Surg (2005) 0.77
Blood pressure and renin-angiotensin system resetting in transgenic rats with elevated plasma Val5-angiotensinogen. J Hypertens (2012) 0.77
Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables. Am J Obstet Gynecol (2006) 0.77
A beat-by-beat cardiovascular index, CARDEAN: a prospective randomized assessment of its utility for the reduction of movement during colonoscopy. Anesth Analg (2010) 0.77
Validation of the Test Your Memory (F-TYM Test) in a French memory clinic population. Clin Neuropsychol (2014) 0.77
Effect of clopidogrel on the steady-state pharmacokinetics of fluvastatin. J Clin Pharmacol (2007) 0.76
Self-perception of quality of life by adolescents with neuromuscular diseases. J Adolesc Health (2009) 0.76
Comparison of different measures of blood pressure. Agreement is not same as correlation. BMJ (2002) 0.75
A positioning pillow to improve lumbar puncture success rate in paediatric haematology-oncology patients: a randomized controlled trial. BMC Cancer (2009) 0.75
Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension. J Hypertens (2014) 0.75
No effect of a homoeopathic combination of Arnica montana and Bryonia alba on bleeding, inflammation, and ischaemia after aortic valve surgery. Br J Clin Pharmacol (2010) 0.75
Distinctive unhealthy eating pattern in free-living middle-aged hypertensives when compared with dyslipidemic or overweight patients. J Hypertens (2013) 0.75
Aortic compliance in healthy subjects: evaluation of tissue Doppler imaging. Ultrasound Med Biol (2004) 0.75
Renin-angiotensin system blockade: to what extent? J Hypertens (2004) 0.75
Increased dietary NaCl potentiates the effects of elevated prorenin levels on blood pressure and organ disease. J Hypertens (2010) 0.75
Unemployment is associated with high cardiovascular event rate and increased all-cause mortality in middle-aged socially privileged individuals. Int Arch Occup Environ Health (2014) 0.75
Carbohydrate-deficient transferrin measured by capillary zone electrophoresis and by turbidimetric immunoassay for identification of young heavy drinkers. Clin Chem (2005) 0.75
Safety and systemic absorption of pulmonary delivered human IFN-beta1a in the nonhuman primate: comparison with subcutaneous dosing. J Interferon Cytokine Res (2002) 0.75
Combining risks estimations and clinical practice guidelines in a computer decision aid: a pilot study of the EsPeR system. Stud Health Technol Inform (2003) 0.75
[Ambulatory blood pressure monitoring must be utilized more often]. Rev Prat (2003) 0.75
[Aging, an issue of the XXI(st) century]. Med Sci (Paris) (2012) 0.75
Evaluation of the agreement between guidelines and initial antihypertensive drug treatment using a national health care reimbursement database. J Eval Clin Pract (2011) 0.75
Functional consequences of angiotensin-converting enzyme gene polymorphism on N-acetyl-Ser-Asp-Lys-Pro degradation and angiotensin II production. J Mol Med (Berl) (2002) 0.75
Obesity, sleep complaints and depression are the cardiovascular risk factors primarily predicted by poor working conditions in the GAZEL cohort. Am J Epidemiol (2017) 0.75
Effect of a nationwide program of educational outreach visits to improve the processes of care for patients with type 2 diabetes. Int J Technol Assess Health Care (2003) 0.75
[What future for a vaccine against tobacco?]. Presse Med (2010) 0.75
[The 2010 years]. Med Sci (Paris) (2015) 0.75